Cargando…

Lessons from effect of etelcalcetide on left ventricular hypertrophy in patients with end-stage kidney disease

Patients with end-stage kidney disease (ESKD) frequently develop left ventricular hypertrophy (LVH), which is associated with an exceptionally high risk of cardiovascular events and mortality. This review focuses on interventional studies that modify levels of fibroblast growth factor 23 (FGF23) and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dörr, Katharina, Kainz, Alexander, Oberbauer, Rainer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	MINERAL METABOLISM: Edited by Aline Martin and Tamara Isakova
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9394497/ https://www.ncbi.nlm.nih.gov/pubmed/35703173 http://dx.doi.org/10.1097/MNH.0000000000000799

Ejemplares similares

Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus
por: Vinke, Joanna Sophia J., et al.
Publicado: (2019)

Bone and heart health in chronic kidney disease: role of dentin matrix protein 1
por: Martin, Aline
Publicado: (2019)

Fibroblast growth factor 23, klotho and heparin
por: Thomas, S. Madison, et al.
Publicado: (2023)

α-Klotho's effects on mineral homeostasis are fibroblast growth factor-23 dependent
por: Erben, Reinhold G.
Publicado: (2018)

Effect of etelcalcetide on cardiac hypertrophy in hemodialysis patients: a randomized controlled trial (ETECAR-HD)
por: Dörr, Katharina, et al.
Publicado: (2019)

Etelcalcetide Inhibits the Progression of Left Atrial Volume Index Compared to Alfacalcidol in Hemodialysis Patients
por: Dörr, Katharina, et al.
Publicado: (2023)

Experience With Anti-Sclerostin Antibody for Osteoporosis Patient With End-Stage Renal Disease on Hemodialysis
por: Mukaddam, Mona Al, et al.
Publicado: (2021)

SAT215 Sagliker Syndrome In A Filipino Female With End Stage Renal Disease
por: Rose Pajanel, Margarette, et al.
Publicado: (2023)

SAT212 Collateral Damage A Case Of Refractory Hyperparathyroidism In A Young Woman With End Stage Renal Disease
por: Alvarado, Ed Wong, et al.
Publicado: (2023)

SUN-507 Parathyroid Carcinoma and Incidental Finding of Hashimoto's Thyroiditis in a Patient with End-Stage Renal Disease: A Case Report
por: Bariuad, Irene Kei, et al.
Publicado: (2019)

Persistent Calciphylaxis and Secondary Hyperparathyroidism in End Stage Renal Disease Patient Due to Ectopic Mediastinal Parathyroid Adenoma- A Case Report
por: Abdelmasih, Randa, et al.
Publicado: (2021)

Effect of etelcalcetide versus alfacalcidol on left ventricular function and feature-tracking cardiac magnetic resonance imaging in hemodialysis—a post-hoc analysis of a randomized, controlled trial
por: Dörr, Katharina, et al.
Publicado: (2023)

SUN-528 The Clinical Utility of Gene Sequencing in Hypophosphatasia: Lessons from Patients with Two Rare Variants
por: Tilden, Daniel, et al.
Publicado: (2019)

SAT-490 Severe Hypercalcemia after Revision of Septic Left Total Knee
por: Zozobrado, Kaye, et al.
Publicado: (2019)

SAT-338 An Unusual Case of Brown Tumor in the Left Femur Associated with Secondary Hyperparathyroidism
por: Garg, Dave, et al.
Publicado: (2020)

MON-349 Left Hip Pseudofracture in a Patient with Refractory Paget Disease of the Bone
por: Gastelum, Alheli Arce, et al.
Publicado: (2020)

ODP127 Trabecular Bone Score and Advanced Glycation End Products In Adults with Type 1 Diabetes
por: Coll, Julie-Catherine, et al.
Publicado: (2022)

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore
por: Khan, Behram A, et al.
Publicado: (2023)

Bone Specific Alkaline Phosphatase and Serum Calcification Propensity Are Not Influenced by Etelcalcetide vs. Alfacalcidol Treatment, and Only Bone Specific Alkaline Phosphatase Is Correlated With Fibroblast Growth Factor 23: Sub-Analysis Results of the ETACAR-HD Study
por: Dörr, Katharina, et al.
Publicado: (2022)

Effects of etelcalcetide on fibroblast growth factor 23 in patients with secondary hyperparathyroidism receiving hemodialysis
por: Wolf, Myles, et al.
Publicado: (2019)

OR13-1 Long-Term Burosumab Therapy Provides Sustained Benefit in Patients with Tumor-Induced Osteomalacia: End of Study Findings From the Pivotal Phase 2 Study
por: Carpenter, Thomas, et al.
Publicado: (2022)

SUN-500 Primary Hyperparathyroidism as Initial Presentation of Stage IV Breast Cancer
por: Magdaleno, Angela, et al.
Publicado: (2019)

ODP652 Challenges in the Management of Hypocalcemia in a Patient with Advanced Stage of Parotid Gland Adenocarcinoma
por: Go, Hannah R, et al.
Publicado: (2022)

SUN-336 Obesity and Impaired Glucose Metabolism in Adult Patients with X-Linked Hypophosphatemia
por: Lecoq, Anne-Lise, et al.
Publicado: (2020)

The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis
por: Coimbra, Susana, et al.
Publicado: (2023)

Managing hyperparathyroidism in hemodialysis: role of etelcalcetide
por: Eidman, Keith E, et al.
Publicado: (2018)

Tania : la guerrillera inolvidable
Publicado: (1974)

Hyperkalemia masking left ventricular hypertrophy in electrocardiogram in a patient with end-stage renal disease
por: Sai Naresh, V. V., et al.
Publicado: (2008)

Moexipril and left ventricular hypertrophy
por: Chrysant, George S, et al.
Publicado: (2007)

Left ventricular hypertrophy: is it really?
por: Mikolich, J Ronald, et al.
Publicado: (2013)

The Effect of FGF23 on Cardiac Hypertrophy Is Not Mediated by Systemic Renin-Angiotensin- Aldosterone System in Hemodialysis
por: Dörr, Katharina, et al.
Publicado: (2022)

Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide
por: Cozzolino, Mario, et al.
Publicado: (2017)

Low agreement between cardiologists diagnosing left ventricular hypertrophy in children with end-stage renal disease
por: Schoenmaker, Nikki J, et al.
Publicado: (2013)

SAT-510 Hypercalcemia Secondary to Vitamin D Intoxication and Nephrocalcinosis in 2 Children
por: Diaz, Alejandro, et al.
Publicado: (2019)

MON-519 Impact of Chronic Hypoparathyroidism on Work, Productivity, and Relationships: Findings from a 13-Country Patient and Caregiver Survey
por: Clarke, Bart, et al.
Publicado: (2019)

MON-518 Osteoporosis in a Young Adult with Trisomy 13
por: Wynn, Anne, et al.
Publicado: (2019)

MON-503 Difficult Decisions in Endocrinology: Unexpected Pregnancy during Diagnosis of TIO
por: Yau, Alice, et al.
Publicado: (2019)

MON-506 Escalating Vitamin D Requirements as the Harbinger of Liver Failure: A Case of Recalcitrant Vitamin D Deficiency Resolved by Liver Transplant
por: Stevenson, Kristin, et al.
Publicado: (2019)

MON-514 Bone Density Yo-yo In A Patient With Severe Hypercalciuria
por: Thakkar, Aditi, et al.
Publicado: (2019)

MON-LB091 An Overview of the Etiology, Clinical Manifestations, Management Strategies, and Complications of Hypoparathyroidism from the Canadian National Hypoparathyroidism Registry
por: Alalawi, Yousef, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_stkl1cl3bi3r6ehle2iqob3g11